Ligand Pharmaceuticals Incorporated (LGND) Insider Trading
- $6,495,870.39
- $226,342,490.90
- March 11, 2026
- John L Higgins
| Trader Name | Date | Title | Amount | Price | Type | Total Value |
|---|---|---|---|---|---|---|
| Jan. 24, 2018 | CEO | 22,500 | $165.00 | Sell | $3,712,500.00 | |
| Jan. 19, 2018 | CEO | 28,099 | $153.70 | Sell | $4,318,816.30 | |
| Jan. 10, 2018 | Director | 2,500 | $145.00 | Sell | $362,500.00 | |
| Dec. 20, 2017 | Director | 925 | $137.25 | Sell | $126,956.25 | |
| Nov. 17, 2017 | VP | 6,559 | $142.63 | Sell | $935,510.17 | |
| Nov. 16, 2017 | Director | 5,000 | $141.71 | Sell | $708,550.00 | |
| Nov. 16, 2017 | CEO | 5,269 | $142.53 | Sell | $750,990.57 | |
| Sept. 5, 2017 | CEO | 5,000 | $130.00 | Sell | $650,000.00 | |
| Aug. 23, 2017 | Director | 2,000 | $127.99 | Sell | $255,980.00 | |
| Aug. 9, 2017 | VP | 18,625 | $126.96 | Sell | $2,364,630.00 | |
| Aug. 9, 2017 | Insider | 6,100 | $127.51 | Sell | $777,811.00 | |
| Aug. 8, 2017 | CEO | 5,483 | $125.00 | Sell | $685,375.00 | |
| June 21, 2017 | CEO | 4,666 | $120.00 | Sell | $559,920.00 | |
| June 9, 2017 | CEO | 12,000 | $114.87 | Sell | $1,378,440.00 | |
| May 12, 2017 | Director | 37,247 | $110.76 | Sell | $4,125,477.72 | |
| May 12, 2017 | Insider | 5,621 | $112.20 | Sell | $630,676.20 | |
| March 20, 2017 | CEO | 4,000 | $109.10 | Sell | $436,400.00 | |
| March 2, 2017 | Insider | 6,879 | $103.39 | Sell | $711,219.81 | |
| Feb. 28, 2017 | Director | 32,000 | $106.35 | Sell | $3,403,200.00 | |
| Nov. 25, 2016 | Director | 18,479 | $107.31 | Sell | $1,982,981.49 | |
| Nov. 18, 2016 | Director | 6,330 | $105.28 | Sell | $666,422.40 | |
| Sept. 22, 2016 | CEO | 3,000 | $117.34 | Sell | $352,020.00 | |
| Sept. 7, 2016 | Director | 1,000 | $115.00 | Sell | $115,000.00 | |
| Sept. 1, 2016 | Director | 1,666 | $105.40 | Sell | $175,596.40 | |
| Aug. 1, 2016 | Director | 1,000 | $137.57 | Sell | $137,570.00 | |
| July 1, 2016 | Director | 1,000 | $121.40 | Sell | $121,400.00 | |
| June 1, 2016 | Director | 1,000 | $117.42 | Sell | $117,420.00 | |
| May 18, 2016 | Director | 334 | $120.50 | Sell | $40,247.00 | |
| May 6, 2016 | Director | 25,000 | $119.20 | Sell | $2,980,000.00 | |
| May 2, 2016 | Director | 1,000 | $121.57 | Sell | $121,570.00 | |
| April 6, 2016 | Director | 5,000 | $115.00 | Sell | $575,000.00 | |
| March 17, 2016 | COO | 6,400 | $96.70 | Sell | $618,880.00 | |
| March 8, 2016 | Director | 6,129 | $101.18 | Sell | $620,132.22 | |
| March 7, 2016 | CEO | 10,833 | $102.47 | Sell | $1,110,057.51 | |
| Jan. 20, 2016 | Director | 1,666 | $94.94 | Sell | $158,170.04 | |
| Nov. 11, 2015 | Director | 7,719 | $101.00 | Sell | $779,619.00 | |
| Aug. 17, 2015 | Director | 4,000 | $95.98 | Sell | $383,920.00 | |
| Aug. 13, 2015 | Director | 49,800 | $96.26 | Sell | $4,793,748.00 | |
| July 10, 2015 | VP | 14,067 | $99.14 | Sell | $1,394,602.38 | |
| June 26, 2015 | COO | 12,500 | $100.97 | Sell | $1,262,125.00 | |
| June 22, 2015 | COO | 23,046 | $96.45 | Sell | $2,222,786.70 | |
| June 10, 2015 | CFO | 4,125 | $93.50 | Sell | $385,687.50 | |
| June 9, 2015 | CEO | 10,000 | $92.88 | Sell | $928,800.00 | |
| June 4, 2015 | Director | 1,640 | $92.68 | Sell | $151,995.20 | |
| May 20, 2015 | Director | 9,240 | $87.34 | Sell | $807,021.60 | |
| May 14, 2015 | CFO | 68,363 | $83.91 | Sell | $5,736,339.33 | |
| March 19, 2015 | Director | 4,591 | $74.42 | Sell | $341,662.22 | |
| Feb. 10, 2015 | VP | 2,300 | $56.34 | Sell | $129,582.00 | |
| Oct. 15, 2014 | Director | 2,000 | $45.68 | Buy | $91,360.00 | |
| Oct. 9, 2014 | Director | 11,000 | $42.99 | Buy | $472,890.00 |
Insiders are both buying and selling Ligand Pharmaceuticals Incorporated stock.
The insider traders at Ligand Pharmaceuticals Incorporated are: John L Higgins, Matthew W Foehr, Jason Aryeh, John W Kozarich, Octavio Espinoza, Matthew E Korenberg, Charles S Berkman, Andrew Reardon, Todd C Davis, Stephen L Sabba, John L Lamattina, Bvf Partners L P/Il, David M Knott, Bvf Partners P/Il, Melanie J Herman, Nishan M Desilva, Sunil Patel, John Sharp, David Knott, Charles Berkman, Matthew Foehr, John Higgins, John W. Kozarich, Melanie J. Herman, Todd Davis, and John Lamattina
The most active insider trader at Ligand Pharmaceuticals Incorporated is John L Higgins with 27 trades.
Bvf Partners P/Il has sold the most Ligand Pharmaceuticals Incorporated stock with a total value of $58,156,493.18.
Bvf Partners L P/Il has bought the most Ligand Pharmaceuticals Incorporated stock with a total value of $2,817,728.47.
The most recent insider trade for Ligand Pharmaceuticals Incorporated was on March 11, 2026.
The single biggest insider buy for Ligand Pharmaceuticals Incorporated was from Todd C Davis with a total value of $1,000,452.00 on May 9, 2025.
The single biggest insider sell for Ligand Pharmaceuticals Incorporated was from Bvf Partners P/Il with a total value of $31,214,249.00 on Feb. 20, 2014.